Results 1 to 10 of about 172,168 (267)
PBA2, a novel inhibitor of the β-catenin/CBP pathway, eradicates chronic myeloid leukemia including BCR-ABL T315I mutation. [PDF]
Yang K +8 more
europepmc +1 more source
In Silico Molecular Modeling of Four New Afatinib Derived Molecules Targeting the Inhibition of the Mutated Form of BCR-ABL T315I. [PDF]
Rocha KML +3 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Effects of a Selective Inhibitor of the Abl Tyrosine Kinase on the Growth of Bcr–Abl Positive Cells
Nature Medicine, 1996Brian Druker +2 more
exaly +2 more sources
A Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects.
Journal of Medicinal Chemistry, 2020The BCR-ABL fusion oncoprotein causes CML or some ALL in Ph+ patients because the ABL kinase is constitutively activated. However, current clinical treatment with ABL inhibitors is seriously limited by the drug resistance and adverse effects.
Yiqing Yang +6 more
semanticscholar +1 more source
Recent advances in Bcr‐Abl tyrosine kinase inhibitors for overriding T315I mutation
Chemical Biology and Drug Design, 2020BCR‐ABL is a gene produced by the fusion of the bcr gene and the c‐abl proto‐oncogene and is considered to be the main cause of chronic myelogenous leukemia (CML) production.
Juan Liu +6 more
semanticscholar +1 more source
Journal of Medicinal Chemistry, 2019
The oncogenic fusion protein BCR-ABL is the driving force of leukemogenesis in chronic myeloid leukemia (CML). Despite great progress for CML treatment through application of tyrosine kinase inhibitors (TKIs) against BCR-ABL, long-term drug ...
Quan-Ju Zhao +14 more
semanticscholar +1 more source
The oncogenic fusion protein BCR-ABL is the driving force of leukemogenesis in chronic myeloid leukemia (CML). Despite great progress for CML treatment through application of tyrosine kinase inhibitors (TKIs) against BCR-ABL, long-term drug ...
Quan-Ju Zhao +14 more
semanticscholar +1 more source
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Science, 2001M. Gorre +6 more
semanticscholar +1 more source
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.
Science, 1990T. Lugo +3 more
semanticscholar +1 more source

